Companies Neogenomics Inc

Neogenomics (NEO): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Neogenomics Inc’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$9,127,092CEO Tony Zook · source

Say-on-pay support83.2%Latest vote · source

CEO vs. named peers56th pct.Of 16 peer CEOs

CEO pay ratio93:1To the median employee · source

CEO pay, last three years

$9,127,092FY2025

CEO total pay was $9,127,092 in fiscal 2025; the brief holds no earlier figure for this CEO.

FY2025: salary $601,539 · bonus $0 · stock awards $3,999,997 · option awards $3,998,235

Executives and directors

Alicia Olivo · General Counsel Gary Passman · Chief Culture Officer Jeffrey Sherman · CFO Christopher Smith · CEO Melody Harris · President Tony Zook · CEO Warren Stone · President David Perez · Independent Director Dr. Alison Hannah · Former director (through FY2025)Dr. Marjorie Green · Independent Director Dr. Neil Gunn · Independent Director Elizabeth Floegel · Former director (through FY2025)Felicia Williams · Independent Director Jack Kenny · Independent Director Lynn Tetrault · Chair of the Board Michael Kelly · Independent Director Stephen Kanovsky · Independent Director

Frequently asked questions

Who was the highest-paid executive at Neogenomics Inc in fiscal 2025?

As disclosed, Tony Zook (Director and Chief Executive Officer) was the highest-paid executive at Neogenomics Inc in fiscal 2025, with total compensation of $9,127,092.

How does Neogenomics Inc's chief executive pay compare to its disclosed peer group?

As disclosed, Tony Zook's total compensation ranked at the 56th percentile of Neogenomics Inc's disclosed peer group.

What is Neogenomics Inc's CEO-to-median employee pay ratio?

As disclosed, Neogenomics Inc's CEO-to-median employee pay ratio was 93:1.

How did shareholders vote on Neogenomics Inc's executive compensation?

As disclosed, 83.2% of shareholders supported Neogenomics Inc's executive compensation in the latest say-on-pay vote.

How much does Neogenomics Inc spend in total on board compensation for fiscal 2025?

As disclosed, Neogenomics Inc reported total board compensation of $2,250,879 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Tony Zook	$601,539	$0	$3,999,997	$3,998,235	$513,400	$0	$13,921	$9,127,092
Director and Chief Executive Officer
Warren Stone	630,069	400,000	2,249,994	1,499,767	275,000	0	14,000	5,068,830
President and Chief Operating Officer
Jeffrey Sherman	603,731	50,000	2,250,000	1,499,697	264,000	0	14,000	4,681,428
Chief Financial Officer
Christopher Smith	310,962	0	3,350,004	0	155,754	0	229,217	4,045,937
Former Director and Former Chief Executive Officer
Melody Harris	269,231	152,329	1,666,652	912,848	0	0	691,385	3,692,445
Former Chief Operations Officer and President, Oncology Data Solutions
Alicia Olivo	522,500	75,000	1,499,997	749,848	196,000	0	6,654	3,049,999
Executive Vice President, General Counsel & Business Development
Gary Passman	447,962	75,000	1,124,995	624,876	164,000	0	6,362	2,443,195
Chief Culture Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Tony Zook	$9,127,092	—	—	—
Warren Stone	5,068,830	3,184,486	3,009,250	↑ +1,884,344
Jeffrey Sherman	4,681,428	3,482,409	3,547,358	↑ +1,199,019
Christopher Smith	4,045,937	11,338,487	11,665,946	↓ −7,292,550
Melody Harris	3,692,445	2,875,377	4,694,225	↑ +817,068
Alicia Olivo	3,049,999	2,236,859	—	↑ +813,140
Gary Passman	2,443,195	—	—	—

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy provides our executive officers with compensation and benefits that are competitive in the market in which we compete for talent and that meet our goals of attracting, retaining, and motivating highly skilled management, which is necessary to create long-term value for our stockholders.

CEO STI target (% of salary)	100%
CEO LTI target (% of salary)	—
Independent consultant	WTW
Clawback policy	true
Anti-hedging	true
Anti-pledging	True

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Alicia Olivo	OPTION	2025-02-21	—	—	107,450	—	$749,848
Warren Stone	OPTION	2025-04-01	—	—	94,518	—	499,973
Alicia Olivo	RSU	2025-02-21	—	—	63,238	—	750,003
Warren Stone	RSU	2025-04-01	—	—	84,317	—	1,000,000
Gary Passman	RSU	2025-02-21	—	—	52,698	—	624,998
Warren Stone	RSU	2025-04-01	—	—	52,687	—	499,999
Jeffrey Sherman	RSU	2025-02-21	—	—	126,476	—	1,500,005
Tony Zook	OPTION	2025-04-01	—	—	729,927	—	3,998,235
Jeffrey Sherman	OPTION	2025-02-21	—	—	214,900	—	1,499,697
Warren Stone	OPTION	2025-04-01	—	—	143,266	—	999,794
Gary Passman	OPTION	2025-02-21	—	—	89,542	—	624,876
Melody Harris	RSU	2025-06-01	—	—	134,034	—	1,666,652
Alicia Olivo	PSU	2025-01-14	—	324,000	59,382	388,800	749,995
Warren Stone	PSU	2025-01-14	—	455,000	59,382	637,000	749,995
Melody Harris	PSU	2025-06-01	—	—	132,162	—	912,848
Christopher Smith	PSU	2025-04-01	—	1,050,000	265,452	2,100,000	3,350,004
Gary Passman	PSU	2025-01-14	—	271,200	39,588	325,440	499,996
Tony Zook	PSU	2025-04-01	—	850,000	421,496	1,700,000	3,999,997
Jeffrey Sherman	PSU	2025-01-14	—	437,500	59,382	612,500	749,995

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Alicia Olivo	$750,003	$749,995	$749,848	33.3%
Warren Stone	1,499,999	749,995	1,499,767	20.0%
Gary Passman	624,998	499,996	624,876	28.6%
Jeffrey Sherman	1,500,005	749,995	1,499,697	20.0%
Tony Zook	0	3,999,997	3,998,235	50.0%
Melody Harris	1,666,652	912,848	0	35.4%
Christopher Smith	0	3,350,004	0	100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Alicia Olivo	RSU	2,646	—	$31,117
Alicia Olivo	Option	5,556	9.45	—
Alicia Olivo	RSU	6,503	—	76,475
Alicia Olivo	RSU	6,841	—	80,450
Warren Stone	PSU	8,954	—	105,299
Warren Stone	RSU	8,954	—	105,299
Alicia Olivo	RSU	8,977	—	105,569
Warren Stone	RSU	9,613	—	113,049
Jeffrey Sherman	RSU	11,151	—	131,136
Gary Passman	PSU	11,651	—	137,016
Gary Passman	RSU	11,651	—	137,016
Warren Stone	RSU	11,939	—	140,403
Alicia Olivo	Option	12,170	19.65	—
Warren Stone	PSU	12,665	—	148,940
Warren Stone	RSU	12,665	—	148,940
Alicia Olivo	PSU	12,665	—	148,940
Alicia Olivo	RSU	12,665	—	148,940
Gary Passman	RSU	12,723	—	149,622
Jeffrey Sherman	RSU	13,006	—	152,951
Alicia Olivo	Option	13,833	10.05	—
Gary Passman	RSU	15,536	—	182,703
Gary Passman	RSU	15,972	—	187,831
Alicia Olivo	Option	16,140	16.45	—
Warren Stone	RSU	16,886	—	198,579
Alicia Olivo	RSU	16,886	—	198,579
Warren Stone	Option	17,990	19.65	—
Alicia Olivo	PSU	19,508	—	229,414
Warren Stone	Option	19,984	13.96	—
Warren Stone	PSU	21,204	—	249,359
Jeffrey Sherman	PSU	22,302	—	262,272
Warren Stone	RSU	22,302	—	262,272
Jeffrey Sherman	PSU	23,303	—	274,043
Jeffrey Sherman	RSU	23,303	—	274,043
Jeffrey Sherman	Option	24,339	19.65	—
Gary Passman	Option	25,972	16.45	—
Warren Stone	Option	26,204	16.45	—
Gary Passman	Option	30,588	11.74	—
Jeffrey Sherman	RSU	31,071	—	365,395
Jeffrey Sherman	PSU	39,016	—	458,828
Gary Passman	RSU	39,588	—	465,555
Warren Stone	Option	41,529	11.21	—
Jeffrey Sherman	Option	49,916	16.45	—
Warren Stone	RSU	52,687	—	619,599
Gary Passman	RSU	52,698	—	619,728
Jeffrey Sherman	RSU	59,382	—	698,332
Warren Stone	RSU	59,382	—	698,332
Alicia Olivo	RSU	59,382	—	698,332
Jeffrey Sherman	Option	62,293	11.62	—
Alicia Olivo	RSU	63,238	—	743,679
Warren Stone	RSU	84,317	—	991,568
Gary Passman	Option	89,542	13.05	—
Warren Stone	Option	94,518	10.44	—
Alicia Olivo	Option	107,450	13.05	—
Jeffrey Sherman	RSU	126,476	—	1,487,358
Melody Harris	RSU	138,013	—	1,601,153
Warren Stone	Option	143,266	13.05	—
Jeffrey Sherman	Option	214,900	13.05	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Dr. Alison HannahIndependent · Departed during FY	$65,842	$276,231	$76,511	$0	$0	$418,584
Lynn TetraultIndependent · Board Chair · Culture and Compensation · Nominating and Corporate Governance	125,150	168,000	72,000	0	0	365,150
Michael KellyIndependent · Audit and Finance (Chair) · Culture and Compensation	79,675	168,000	72,000	0	0	319,675
David PerezIndependent · Culture and Compensation (Chair) · Audit and Finance · Innovation, Pipeline and Technology	79,300	168,000	72,000	0	0	319,300
Dr. Neil GunnIndependent · Innovation, Pipeline and Technology (Chair) · Culture and Compensation · Nominating and Corporate Governance	72,500	168,000	72,000	0	0	312,500
Felicia WilliamsIndependent · Audit and Finance · Nominating and Corporate Governance	65,000	168,000	72,000	0	0	305,000
Stephen KanovskyIndependent · Nominating and Corporate Governance (Chair) · Compliance	62,921	168,000	72,000	0	0	302,921
Elizabeth FloegelIndependent · Departed during FY	38,628	168,000	72,000	0	0	278,628
Dr. Marjorie GreenIndependent · Innovation, Pipeline and Technology · Partial-year service · Newly elected	28,832	159,600	68,400	0	0	256,832
Anthony P. ZookEmployee director · Innovation, Pipeline and Technology	21,200	—	—	—	0	21,200
Jack KennyIndependent · Innovation, Pipeline and Technology · Partial-year service · Newly elected	0	0	0	0	0	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$240,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 15,000 / 10,000
Stock ownership guideline	achieve an ownership target of NeoGenomics stock equal to or greater than three times the value of the annual retainer paid to such director

Total cost of the board

Component	FY2025
Cash retainers and fees	$639,048
Equity awards (grant-date value)	$1,611,831
All other compensation	$0
Total cost of the board	$2,250,879

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Neogenomics as a peer

Companies that benchmark against NEO

16 companies name NEO as a compensation peer

10x Genomics, Inc.TXGFY2025
Adaptive Biotechnologies CorpADPTFY2025
CareDx, Inc.CDNAFY2025
Chrome Holding Co.MEFY2024
Fulgent Genetics, Inc.FLGTFY2025
GeneDx Holdings Corp.WGSFY2025
Guardant Health, Inc.GHFY2025
MESA LABORATORIES INC /CO/MLABFY2026
MYRIAD GENETICS INCMYGNFY2025
NEOGEN CORPNEOGFY2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACBFY2025
Progyny, Inc.PGNYFY2025
STANDARD BIOTOOLS INC.LABFY2025
Twist Bioscience CorpTWSTFY2025
VERACYTE, INC.VCYTFY2025

Each company listed discloses NEO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NEO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

CDNA CareDx, Inc.ATRC AtriCure, Inc.MRVI Maravai Life Sciences Holdings, Inc.TXG 10x Genomics, Inc.FLGT Fulgent Genetics, Inc.NTRA Natera, Inc.ADPT Adaptive Biotechnologies CorporationGH Guardant Health, Inc.OPK OPKO Health, Inc.IRTC iRhythm Technologies, Inc.QDEL QuidelOrtho CorporationVCYT Veracyte, Inc.EBS Emergent BioSolutions, Inc.MEDP Medpace Holdings, Inc.EXAS Exact Sciences CorporationMYGN Myriad Genetics, Inc.

Peer reciprocity

The companies Neogenomics Inc names as compensation peers that name it back in their own disclosed peer groups.

CareDx, Inc. (CDNA)¹²⁰10x Genomics, Inc. (TXG)¹²¹Fulgent Genetics, Inc. (FLGT)¹²²Adaptive Biotechnologies Corporation (ADPT)¹²³Guardant Health, Inc. (GH)¹²⁴Veracyte, Inc. (VCYT)¹²⁵

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Exact Sciences Corporation	2024	Kevin Conroy	$1,083,368	$13,496,138	$0	$712,329	$15,539,378
2	Natera, Inc.	2025	Steven Chapman	853,710	12,979,558	0	1,114,151	14,957,319
3	Medpace Holdings, Inc.	2025	August Troendle	937,417	0	9,999,999	0	11,443,766
4	QuidelOrtho Corporation	2025	Brian Blaser	1,000,000	8,965,822	0	1,274,500	11,255,782
5	iRhythm Technologies, Inc.	2025	Quentin Blackford	700,003	8,919,457	0	1,350,000	11,003,163
6	Maravai Life Sciences Holdings, Inc.	2025	Bernd Brust	388,863	7,660,000	1,460,000	425,343	10,129,708
7	AtriCure, Inc.	2025	Michael Carrel	828,439	7,203,478	0	1,171,703	9,217,620
8	Neogenomics Inc	2025	Tony Zook	601,539	3,999,997	3,998,235	513,400	9,127,092
9	Adaptive Biotechnologies Corporation	2025	Chad Robins	698,258	7,675,100	0	703,380	9,081,690
10	Guardant Health, Inc.	2025	AmirAli Talasaz	1	8,647,709	0	0	8,661,227
11	Veracyte, Inc.	2025	Marc Stapley	700,000	5,890,877	0	826,000	7,421,877
12	CareDx, Inc.	2025	John Hanna	693,269	5,622,638	0	852,515	7,179,699
13	10x Genomics, Inc.	2025	Serge Saxonov	674,250	5,020,269	0	634,725	6,329,244
14	Fulgent Genetics, Inc.	2025	Ming Hsieh	1,000,000	4,000,000	0	1,207,000	6,207,000
15	Myriad Genetics, Inc.	2025	Samraat Raha	856,901	3,989,729	0	814,660	5,686,740
16	Emergent BioSolutions, Inc.	2025	Joseph Papa	1,037,385	1,638,500	1,191,500	1,446,640	5,321,147
17	Opko Health, Inc.	2025	Phillip Frost	960,000	0	400,000	0	1,854,000

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Neogenomics Inc	60%	RSU 50 · Options 50	not disclosed	WTW
10x Genomics, Inc.	93%	PSU 60 · RSU 40	Yes — 3-year Relative TSR	Alpine Rewards LLC
Adaptive Biotechnologies Corporation	not disclosed	RSU 50 · PSU 50	not disclosed	Semler Brossy Consulting Group, LLC
AtriCure, Inc.	not disclosed	PSU 70 · RSU 30	No	Korn Ferry
CareDx, Inc.	not disclosed	RSU 70 · PRSU 30	No	Alpine Rewards
Emergent BioSolutions, Inc.	107%	Options 50 · PSU 50	No	WTW
Exact Sciences Corporation	47%	PSU 60 · RSU 40	No	Aon
Fulgent Genetics, Inc.	120.7%	PSU 60 · RSU 40	No	USI
Guardant Health, Inc.	140%	PSU 50 · RSU 50 · Option 35	No	Aon
iRhythm Technologies, Inc.	173%	RSU 50 · PSU 50	Yes — Relative TSR	Aon and Mercer
Maravai Life Sciences Holdings, Inc.	not disclosed	not disclosed	No	Meridian Compensation Partners, LLC
Medpace Holdings, Inc.	52.5%	Options 100	not disclosed	Total Compensation Solutions (TCS)
Myriad Genetics, Inc.	89%	RSU 50 · PSU 50	Yes	Mercer, LLC
Natera, Inc.	131.1%	PSU 50 · RSU 50	No	Aon
Opko Health, Inc.	not disclosed	not disclosed	not disclosed	not disclosed
QuidelOrtho Corporation	not disclosed	PSU 60 · RSU 40	Yes — Total Shareholder Return (TSR)	Compensia
Veracyte, Inc.	118%	PSU 50 · RSU 50	No	Aon

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-05-21	91,781,833	18,534,236	56,118	83.2%	Passed
2025	2025-05-22	87,823,189	19,573,234	103,117	81.77%	Passed
2024	2024-05-23	76,045,753	33,308,929	719,851	69.54%	Passed
2023	2023-05-25	54,790,033	47,993,647	2,998,666	53.31%	Passed
2022	2022-06-02	29,671,036	66,847,771	510,791	30.74%	Failed
2021	2021-05-27	90,931,692	8,059,423	229,266	91.86%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-05-21	83.2%^a
2025	2025-05-22	81.77%^b
2024	2024-05-23	69.54%^c

a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of voting on this Proposal 3.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 1.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of Proposal 1.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	93 : 1
CEO total compensation	$9,375,553
Median employee compensation	$101,144

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Alicia Olivo	EVP, GC & Business Development	2026-05-01	D	1,042	$0	$0	Common	Form 4 ↗
Greg D. Aunan	Chief Accounting Officer	2026-05-01	D	937	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-05-02	D	5,969	0	0	Derivative, Class A Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-05-02	D	2,349	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-05-02	A	5,969	0	0	Common	Form 4 ↗
Greg D. Aunan	Chief Accounting Officer	2026-05-02	D	5,372	0	0	Derivative, Class A Common	Form 4 ↗
Greg D. Aunan	Chief Accounting Officer	2026-05-02	D	1,309	0	0	Common	Form 4 ↗
Greg D. Aunan	Chief Accounting Officer	2026-05-02	A	5,372	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-05-11	D	3,783	0	0	Common	Form 4 ↗
Alicia Olivo	EVP, GC & Business Development	2026-05-11	D	3,944	0	0	Derivative, Class A Common	Form 4 ↗
Alicia Olivo	EVP, GC & Business Development	2026-05-11	D	2,559	0	0	Common	Form 4 ↗
Alicia Olivo	EVP, GC & Business Development	2026-05-11	A	3,944	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-05-11	D	5,830	0	0	Derivative, Class A Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-05-11	A	5,830	0	0	Common	Form 4 ↗
Lynn Tetrault	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Dr. Neil Gunn	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Dr. Neil Gunn	Director	2026-06-01	A	23,077	0	0	Common	Form 4 ↗
Stephen Kanovsky	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
Stephen Kanovsky	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Stephen Kanovsky	Director	2026-06-01	A	23,077	0	0	Common	Form 4 ↗
Michael Kelly	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
Lynn Tetrault	Director	2026-06-01	D	23,077	0	0	Derivative, Class A Common	Form 4 ↗
Felicia Williams	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
Felicia Williams	Director	2026-06-01	D	23,077	0	0	Derivative, Class A Common	Form 4 ↗
Jack Kenny	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Jack Kenny	Director	2026-06-01	D	5,893	0	0	Derivative, Class A Common	Form 4 ↗
Michael Kelly	Director	2026-06-01	A	23,077	0	0	Common	Form 4 ↗
Felicia Williams	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Dr. Marjorie Green	Director	2026-06-01	D	22,964	0	0	Derivative, Class A Common	Form 4 ↗
Dr. Marjorie Green	Director	2026-06-01	A	22,964	0	0	Common	Form 4 ↗
Dr. Neil Gunn	Director	2026-06-01	D	23,077	0	0	Derivative, Class A Common	Form 4 ↗
Stephen Kanovsky	Director	2026-06-01	D	23,077	0	0	Derivative, Class A Common	Form 4 ↗
Michael Kelly	Director	2026-06-01	D	23,077	0	0	Derivative, Class A Common	Form 4 ↗
David Perez	Director	2026-06-01	D	23,077	0	0	Derivative, Class A Common	Form 4 ↗
Lynn Tetrault	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
Felicia Williams	Director	2026-06-01	A	23,077	0	0	Common	Form 4 ↗
Jack Kenny	Director	2026-06-01	A	5,893	0	0	Common	Form 4 ↗
Dr. Marjorie Green	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
David Perez	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Jack Kenny	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
Dr. Neil Gunn	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
David Perez	Director	2026-06-01	A	15,970	0	0	Derivative, Class A Common	Form 4 ↗
David Perez	Director	2026-06-01	A	23,077	0	0	Common	Form 4 ↗
Lynn Tetrault	Director	2026-06-01	A	23,077	0	0	Common	Form 4 ↗
Michael Kelly	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Dr. Marjorie Green	Director	2026-06-01	A	11,069	0	0	Derivative, Class A Common	Form 4 ↗
Lynn Tetrault	Director	2026-06-09	D	5,307	11	59,916	Common	Form 4 ↗
Lynn Tetrault	Director	2026-06-15	D	5,307	11	58,908	Common	Form 4 ↗
Carolyn S. Starrett	Director	2026-06-23	A	9,784	0	0	Derivative, Class A Common	Form 4 ↗
Carolyn S. Starrett	Director	2026-06-23	A	14,125	0	0	Derivative, Class A Common	Form 4 ↗
Greg D. Aunan	Chief Accounting Officer	2026-08-04	D	20,000	16	321,400	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-08-21	D	11,060	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-08-21	A	28,106	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-08-21	D	28,106	0	0	Derivative, Class A Common	Form 4 ↗
Alicia Olivo	EVP, GC & Business Development	2026-09-01	D	2,692	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-10-01	D	17,562	0	0	Derivative, Class A Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-10-01	D	6,911	0	0	Common	Form 4 ↗
Warren Stone	Pres & Chief Operating Officer	2026-10-01	A	17,562	0	0	Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (125 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Tony Zook. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 9,127,092. View filing ↗
Section 01, Warren Stone. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 5,068,830. View filing ↗
Section 01, Jeffrey Sherman. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 4,681,428. View filing ↗
Section 01, Christopher Smith. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 4,045,937. View filing ↗
Section 01, Melody Harris. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 3,692,445. View filing ↗
Section 01, Alicia Olivo. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 3,049,999. View filing ↗
Section 01, Gary Passman. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 52. As printed: 2,443,195. View filing ↗
Section 03, Alicia Olivo OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Warren Stone OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Alicia Olivo RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Warren Stone RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Gary Passman RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Warren Stone RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeffrey Sherman RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tony Zook OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeffrey Sherman OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Warren Stone OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Gary Passman OPTION. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Melody Harris RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Alicia Olivo PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Warren Stone PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Melody Harris PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Christopher Smith PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Gary Passman PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Tony Zook PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Jeffrey Sherman PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-06. Section “CEO Pay Ratio”. As printed: 93 : 1. View filing ↗
Section 08, Dr. Alison Hannah. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 418,584. View filing ↗
Section 08, Lynn Tetrault. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 365,150. View filing ↗
Section 08, Michael Kelly. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 319,675. View filing ↗
Section 08, David Perez. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 319,300. View filing ↗
Section 08, Dr. Neil Gunn. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 312,500. View filing ↗
Section 08, Felicia Williams. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 305,000. View filing ↗
Section 08, Stephen Kanovsky. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 302,921. View filing ↗
Section 08, Elizabeth Floegel. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 278,628. View filing ↗
Section 08, Dr. Marjorie Green. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 256,832. View filing ↗
Section 08, Anthony P. Zook. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 21,200. View filing ↗
Section 08, Jack Kenny. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Alicia Olivo 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Greg D. Aunan 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-05-02. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-05-02. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-05-02. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Greg D. Aunan 2026-05-02. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Greg D. Aunan 2026-05-02. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Greg D. Aunan 2026-05-02. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Alicia Olivo 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Alicia Olivo 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Alicia Olivo 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lynn Tetrault 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Neil Gunn 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Neil Gunn 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Kanovsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Kanovsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Kanovsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Kelly 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lynn Tetrault 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Felicia Williams 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Felicia Williams 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jack Kenny 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jack Kenny 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Kelly 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Felicia Williams 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Marjorie Green 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Marjorie Green 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Neil Gunn 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Stephen Kanovsky 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Kelly 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Perez 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lynn Tetrault 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Felicia Williams 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jack Kenny 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Marjorie Green 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Perez 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Jack Kenny 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Neil Gunn 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Perez 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Perez 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lynn Tetrault 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Michael Kelly 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Dr. Marjorie Green 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lynn Tetrault 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lynn Tetrault 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Carolyn S. Starrett 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Carolyn S. Starrett 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Greg D. Aunan 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Alicia Olivo 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Warren Stone 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-05-22. Item 5.07 · say-on-pay result. As reported: 83.2% (votes for as printed: 91,781,833). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-05-27. Item 5.07 · say-on-pay result. As reported: 81.77% (votes for as printed: 87,823,189). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-05-24. Item 5.07 · say-on-pay result. As reported: 69.54% (votes for as printed: 76,045,753). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 639,048 + equity 1,611,831 + all other 0 = 2,250,879, summed across the director compensation table rows.
Exact Sciences Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. View filing ↗
Natera, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. View filing ↗
Medpace Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. View filing ↗
QuidelOrtho Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. View filing ↗
iRhythm Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. View filing ↗
Maravai Life Sciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Maravai Life Sciences Holdings, Inc.'s own proxy. As printed: 10,129,708. View filing ↗
AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
Neogenomics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Neogenomics Inc's own proxy. As printed: 9,127,092. View filing ↗
Adaptive Biotechnologies Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. View filing ↗
Guardant Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. View filing ↗
Veracyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. View filing ↗
CareDx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
10x Genomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. View filing ↗
Fulgent Genetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. View filing ↗
Myriad Genetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. View filing ↗
Emergent BioSolutions, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Emergent BioSolutions, Inc.'s own proxy. As printed: 5,321,147. View filing ↗
Opko Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Opko Health, Inc.'s own proxy. As printed: 1,854,000. View filing ↗
Section 10a, CareDx, Inc. reciprocity. DEF 14A. CareDx, Inc. names Neogenomics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, 10x Genomics, Inc. reciprocity. DEF 14A. 10x Genomics, Inc. names Neogenomics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Fulgent Genetics, Inc. reciprocity. DEF 14A. Fulgent Genetics, Inc. names Neogenomics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Adaptive Biotechnologies Corporation reciprocity. DEF 14A. Adaptive Biotechnologies Corporation names Neogenomics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Guardant Health, Inc. reciprocity. DEF 14A. Guardant Health, Inc. names Neogenomics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Veracyte, Inc. reciprocity. DEF 14A. Veracyte, Inc. names Neogenomics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗